DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 37 filers reported holding DICERNA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $74,737,000 | -44.7% | 3,707,210 | +2.4% | 0.00% | -33.3% |
| Q2 2021 | $135,112,000 | +48.1% | 3,620,353 | +1.5% | 0.00% | +50.0% |
| Q1 2021 | $91,224,000 | +23.4% | 3,567,645 | +6.3% | 0.00% | 0.0% |
| Q4 2020 | $73,926,000 | +26.9% | 3,355,719 | +3.6% | 0.00% | 0.0% |
| Q3 2020 | $58,271,000 | -31.3% | 3,239,062 | -2.9% | 0.00% | -33.3% |
| Q2 2020 | $84,760,000 | +56.3% | 3,336,975 | +13.0% | 0.00% | +50.0% |
| Q1 2020 | $54,225,000 | -13.1% | 2,951,857 | +4.2% | 0.00% | 0.0% |
| Q4 2019 | $62,394,000 | +70.0% | 2,832,199 | +10.8% | 0.00% | +100.0% |
| Q3 2019 | $36,693,000 | -0.4% | 2,555,272 | +9.2% | 0.00% | 0.0% |
| Q2 2019 | $36,842,000 | +9.2% | 2,339,194 | +1.6% | 0.00% | 0.0% |
| Q1 2019 | $33,743,000 | +34.9% | 2,303,289 | -1.6% | 0.00% | 0.0% |
| Q4 2018 | $25,021,000 | -17.3% | 2,340,608 | +18.0% | 0.00% | 0.0% |
| Q3 2018 | $30,265,000 | +75.2% | 1,983,272 | +40.7% | 0.00% | 0.0% |
| Q2 2018 | $17,273,000 | +46.9% | 1,410,075 | +14.6% | 0.00% | 0.0% |
| Q1 2018 | $11,762,000 | +120.9% | 1,230,400 | +108.7% | 0.00% | – |
| Q4 2017 | $5,324,000 | +112.1% | 589,573 | +35.0% | 0.00% | – |
| Q3 2017 | $2,510,000 | +132.8% | 436,665 | +28.3% | 0.00% | – |
| Q2 2017 | $1,078,000 | -2.7% | 340,327 | +4.5% | 0.00% | – |
| Q1 2017 | $1,108,000 | +18.5% | 325,810 | +0.3% | 0.00% | – |
| Q4 2016 | $935,000 | -67.4% | 324,724 | -33.4% | 0.00% | – |
| Q3 2016 | $2,869,000 | +79.8% | 487,885 | -8.3% | 0.00% | – |
| Q2 2016 | $1,596,000 | -45.7% | 532,070 | -3.0% | 0.00% | – |
| Q1 2016 | $2,941,000 | -52.5% | 548,692 | +5.3% | 0.00% | – |
| Q4 2015 | $6,187,000 | -96.2% | 521,226 | -90.3% | 0.00% | -100.0% |
| Q3 2015 | $161,765,000 | +2617.4% | 5,367,722 | +1157.8% | 0.01% | – |
| Q2 2015 | $5,953,000 | -17.0% | 426,746 | +42.9% | 0.00% | – |
| Q1 2015 | $7,176,000 | +83.2% | 298,601 | +25.6% | 0.00% | – |
| Q4 2014 | $3,916,000 | +57.5% | 237,794 | +21.8% | 0.00% | – |
| Q3 2014 | $2,486,000 | -6.7% | 195,240 | +65.3% | 0.00% | – |
| Q2 2014 | $2,665,000 | +39.3% | 118,085 | +74.4% | 0.00% | – |
| Q1 2014 | $1,913,000 | – | 67,721 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,355,392 | $29,859,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $67,858,000 | 4.26% |
| DAFNA Capital Management LLC | 587,756 | $12,948,000 | 3.85% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 227,388 | $5,009,000 | 2.91% |
| RTW INVESTMENTS, LP | 7,253,857 | $159,802,000 | 2.68% |
| Parkman Healthcare Partners LLC | 331,513 | $7,303,000 | 1.87% |
| Evolutionary Tree Capital Management, LLC | 60,864 | $1,341,000 | 1.02% |
| Eagle Health Investments LP | 69,000 | $1,520,000 | 0.97% |
| Woodline Partners LP | 1,358,796 | $29,934,000 | 0.79% |
| Affinity Asset Advisors, LLC | 40,000 | $881,000 | 0.47% |